1
|
Esposito A, De Gregorio E, De Fenza M, D'Alonzo D, Satawani A, Guaragna A. Expeditious synthesis and preliminary antimicrobial activity of deflazacort and its precursors. RSC Adv 2019; 9:21519-21524. [PMID: 35521350 PMCID: PMC9066171 DOI: 10.1039/c9ra03673c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 07/04/2019] [Indexed: 01/30/2023] Open
Abstract
Synthesis of deflazacort: unexpected antibacterial activity of its epoxide synthetic precursor.
Collapse
Affiliation(s)
- Anna Esposito
- Department of Chemical Sciences
- University of Napoli Federico II
- 80126 Napoli
- Italy
| | - Eliana De Gregorio
- Department of Molecular Medicine and Medical Biotechnologies
- 80131 Napoli
- Italy
| | - Maria De Fenza
- Department of Chemical Sciences
- University of Napoli Federico II
- 80126 Napoli
- Italy
| | - Daniele D'Alonzo
- Department of Chemical Sciences
- University of Napoli Federico II
- 80126 Napoli
- Italy
| | | | - Annalisa Guaragna
- Department of Chemical Sciences
- University of Napoli Federico II
- 80126 Napoli
- Italy
| |
Collapse
|
2
|
Bashir MSM, Saleem M, Choudhari U. Deflazacort-induced Acneiform Eruptions. J Pharm Bioallied Sci 2018; 9:284-286. [PMID: 29456382 PMCID: PMC5810081 DOI: 10.4103/jpbs.jpbs_67_17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
A 38-year-old male suffering from a low backache since 3 months was diagnosed as a case of L4-L5 disc prolapse after magnetic resonance imaging examination. He was treated with tolperisone, aceclofenac, and paracetamol in these drugs deflazacort added later. From the 2nd day of an addition of deflazacort in the therapy, sharply marginated, infiltrative, and erythematous skin eruptions with discrete itching sensations were seen. It was diagnosed as deflazacort-induced acneiform eruption and treated with doxycycline for 2 months which led to the disappearance of acneiform eruptions.
Collapse
Affiliation(s)
| | - Mohammad Saleem
- Department of Anatomy, NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Maharashtra, India
| | - Uday Choudhari
- Department of Skin & VD, Consultant Dermatologist, Nagpur, India
| |
Collapse
|
3
|
Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study. Lupus 2018; 27:890-898. [PMID: 29320974 DOI: 10.1177/0961203317751854] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Deflazacort (DFZ), an oxazoline derivative of prednisolone (PDN), has a dose equivalence of 1.2:1 (mg) to PDN. No study to date has compared adverse effects and efficacy of high doses of DFZ as against high-dose PDN in systemic lupus erythematosus (SLE). OBJECTIVES To compare adverse effects of high dose DFZ and PDN in SLE patients, especially in terms of cushingoid features and gain in body weight, 3 and 6 months after initiation of these agents. METHODS In both the steroid arms, the following outcome parameters were assessed at 3 and 6 months: (a) cushingoid features by Cushing's Severity Index (CSI) (b) hirsutism by modified Ferriman Gallwey score (c) weight gain by difference (Δ, delta) of weight (in kilograms). RESULTS Patients on PDN had 1.6 kg (3.2%) and 2 kg (5.1%) higher median weight gain as compared to those on DFZ at 3 and 6 months respectively ( p = 0.012 and 0.001). PDN caused 10% and 22.2% higher increment in median hirsutism scores as compared to DFZ at 3 months and 6 months follow-up, respectively ( p = 0.004 and 0.002). PDN caused 100% higher increase in median CSI scores than DFZ at 6 months ( p = 0.03). There was no significant difference by generalized estimation equation between the groups with respect to changes in SLEDAI, renal SLEDAI, anti-dsDNA titres and C3/C4 levels. There were two serious infections (requiring hospitalization/intravenous antibiotics) in the PDN group, while none in the DFZ group. CONCLUSION Comparable intake and tapering of high dose DFZ and PDN in active SLE revealed 2-fold less weight gain, 2.5-fold less hirsutism and 1.5-fold lower cushingoid severity index as well as lower glycaemic elevation in the DFZ group as compared to PDN group. Both had similar efficacy.
Collapse
Affiliation(s)
- A Ganapati
- Department of Clinical Immunology and Rheumatology, 30025 Christian Medical College, Vellore , India
| | - R Ravindran
- Department of Clinical Immunology and Rheumatology, 30025 Christian Medical College, Vellore , India
| | - T David
- Department of Medicine II, 30025 Christian Medical College, Vellore , India
| | - B Yadav
- Department of Biostatistics, 30025 Christian Medical College, Vellore , India
| | - V Jeyaseelan
- Department of Biostatistics, 30025 Christian Medical College, Vellore , India
| | - L Jeyaseelan
- Department of Biostatistics, 30025 Christian Medical College, Vellore , India
| | - D Danda
- Department of Clinical Immunology and Rheumatology, 30025 Christian Medical College, Vellore , India
| |
Collapse
|
4
|
Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, Tekade RK. Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. J Biomed Res 2017; 30:149-161. [PMID: 28276670 PMCID: PMC4820892 DOI: 10.7555/jbr.30.20150074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Revised: 06/02/2015] [Accepted: 12/25/2015] [Indexed: 11/03/2022] Open
Abstract
In this investigation, sensitive and reproducible methods are described for quantitative determination of deflazacort in the presence of its degradation product. The method was based on high performance liquid chromatography of the drug from its degradation product on reverse phase using Acquity UPLC BEH C18 columns (1.7 µm, 2.1 mm × 150 mm) using acetonitrile and water (40:60 V/V) at a flow rate of 0.2 mL/minute in UPLC. UV detection was performed at 240.1 nm. Deflazacort was subjected to oxidative, acid, base, hydrolytic, thermal and photolytic degradation. The drug was found to be stable in water and thermal stress, as well as under neutral stress conditions. However, forced-degradation study performed on deflazacort showed that the drug degraded under alkaline, acid and photolytic stress. The degradation products were well resolved from the main peak, which proved the stability-indicating power of the method. The developed method was validated as per ICH guidelines with respect to accuracy, linearity, limit of detection, limit of quantification, accuracy, precision and robustness, selectivity and specificity. Apart from the aforementioned, the results of the present study also emphasize the importance of isolation characterization and identification of degradant. Hence, an attempt was made to identify the degradants in deflazacort. One of the degradation products of deflazacort was isolated and identified by the FTIR, NMR and LC-MS study.
Collapse
Affiliation(s)
- Rajesh Deshmukh
- Macleods Pharmaceuticals Ltd., Kachigam, Daman, 396320, India
| | - Lata Sharma
- School of Pharmaceutical Science, Rajiv Gandhi Prodyogiki Vishwavidyalaya, Gandhi Nagar, Bhopal 462036, India
| | - Muktika Tekade
- TIT College of Pharmacy, Technocrats Institute of Technology, Anand Nagar, Bhopal 462021, India
| | - Prashant Kesharwani
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
| | - Piyush Trivedi
- School of Pharmaceutical Science, Rajiv Gandhi Prodyogiki Vishwavidyalaya, Gandhi Nagar, Bhopal 462036, India
| | - Rakesh K Tekade
- The University of Texas Southwestern Medical Center, Advanced Imaging Research Center, Dallas, TX 75390, USA.,The International Medical University, School of Pharmacy, Department of Pharmaceutical Technology, Kuala Lumpur, 57000, Malaysia; and
| |
Collapse
|
5
|
Abstract
Steroids form an important component of dermatological therapy and are used since very long time for different conditions in different forms. Though very few molecules are used since very long time, the side effect associated with this group of drugs are almost always there. Recently a new molecule deflazacort has been introduced into Indian market, is a glucocorticoid and a derivative of old molecule prednisolone. Though claimed to be having less side effect, very few studies have been done in Indian prospective. This review will highlight the very basics of this drug and its advantages and disadvantages.
Collapse
Affiliation(s)
- Surajit Nayak
- Department of Skin and VD, MKCG Medical College and Hospital, Berhampur, Orissa 760004, India.
| | | |
Collapse
|
6
|
Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity. Adv Ther 2007; 24:1052-60. [PMID: 18029332 DOI: 10.1007/bf02877711] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Deflazacort (DFZ) is a synthetic glucocorticoid that has few adverse effects on glucose and calcium metabolism and fewer deleterious effects on the neuronal population. Therefore, it may have a crucial role in the treatment of patients with autoimmune disorders associated with central nervous system or metabolic affectations. To date, the pharmacologic safety profile of DFZ is considered similar to that of other glucocorticoids. Nevertheless, cumulative clinical and laboratory evidence suggests that DFZ has, in fact, greater immunosuppressive activity than was previously thought. Therefore, it is possible that DFZ increases the risk of acquiring opportunistic infection compared with other synthetic glucocorticoids. Additional pharmacologic studies are needed to fully establish the immunosuppressive potency of DFZ and, consequently, to determine the appropriate ratio of bioequivalence in humans.
Collapse
|
7
|
Ferraris JR, Pasqualini T, Alonso G, Legal S, Sorroche P, Galich AM, Jasper H. Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients. Pediatr Nephrol 2007; 22:734-41. [PMID: 17294225 DOI: 10.1007/s00467-006-0403-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2006] [Revised: 11/21/2006] [Accepted: 11/21/2006] [Indexed: 11/28/2022]
Abstract
Metabolic effects of deflazacort vs. methylprednisone were studied in prepubertal patients after kidney transplantation. Thirty-one patients participated: 15 received deflazacort and 16 remained on methylprednisone. The study started at a mean of 2.1 years after transplantation, when patients were randomized to either continue with methylprednisone or switch to deflazacort. Height velocity increased more in the deflazacort than in the methylprednisone group only during the first 2 years: 5.4 +/- 0.5 vs. 3.5 +/- 0.3 cm/year, and 4.2 +/- 0.8 vs. 2.2 +/- 0.4 cm/year p=0.007, [by two-way analysis of variance (ANOVA)]. After 2 and 3 years, the number of patients who were overweight increased in the methylprednisone group and decreased in the deflazacort group; p<0.01. Lean body mass increased more in the deflazacort than in the methylprednisone group (p=0.003). Fat body mass increased only in the methylprednisone group (p<0.01). Total cholesterol and low-density-lipoprotein (LDL) cholesterol increased in the methylprednisone group (p<0.05 and p<0.01, respectively). Total and LDL cholesterol were reduced (p<0.01 and p<0.001, respectively), whereas high-density-lipoprotein (HDL) cholesterol increased (p<0.001) during deflazacort therapy. Lumbar spine bone mineral density (BMD) decreased in both groups, but total skeleton BMD decreased only in the methylprednisone group (p<0.001). Finally, normal glucose/insulin ratio, defined as > 7, was associated (p<0.05) with the deflazacort group. Our data suggest that deflazacort therapy might improve linear growth and lean body mass and prevent excessive bone loss and fat accumulation. It also leads to an improvement in lipoprotein profile without reduction in insulin sensitivity.
Collapse
Affiliation(s)
- Jorge R Ferraris
- Sección Trasplante Renal Pediátrico, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
| | | | | | | | | | | | | |
Collapse
|
8
|
Gonzalez-Castañeda RE, Castellanos-Alvarado EA, Flores-Marquez MR, Gonzalez-Perez O, Luquin S, Garcia-Estrada J, Ramos-Remus C. Deflazacort induced stronger immunosuppression than expected. Clin Rheumatol 2006; 26:935-40. [PMID: 16738843 DOI: 10.1007/s10067-006-0223-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2005] [Revised: 01/23/2006] [Accepted: 01/23/2006] [Indexed: 11/30/2022]
Abstract
Prednisone (PDN) impairs cognitive functioning and brain structures in humans and animals. Deflazacort (DFZ) is a synthetic glucocorticoid claimed to have lesser side effects than prednisone. The objective of this study was to assess whether chronic administration (90 days) of DFZ produces less neuronal degeneration and glial reactivity than PDN. Male Swiss-Wistar rats were studied. Controls received 0.1 ml distilled water orally. The PDN group received prednisone 5 mg per kg per day orally, and the DFZ group received deflazacort 6 mg per kg per day orally. This model had to be assembled in three different occasions due to excess mortality in the DFZ group. A fourth model was assembled using only the DFZ group and slides of water and PDN-exposed rats from a previous study were used as comparators. The index of degenerated neurons and the number and cytoplasmic transformation of astrocytes and microglia cells were evaluated in the prefrontal cortex, CA1, and CA3 hippocampus. The results show that the overall mortality was 49% in the DFZ group, 4.5% in the PDN group, and none of the controls died. Routine necropsy showed infection in multiple organs. The PDN group had two times higher neuronal degeneration in the prefrontal cortex, almost 11 times in CA1, and four times in CA3 hippocampus when compared with controls and DFZ group. Astrocytes reactivity was increased in the PDN- and DFZ-exposed rats compared with controls. The DFZ group showed an average of four times less microgial cells in the three studied regions when compared with controls and the PDN group. In conclusion, it seems that DFZ at the equivalent licensed dose produced a stronger immunosuppressive effect--systemic and in brain tissue--than PDN, but induced less neuronal damage. The immunosuppressant magnitude of DFZ should be further studied in clinical settings.
Collapse
Affiliation(s)
- Rocio E Gonzalez-Castañeda
- Neuroscience Division, Centro de Investigación Biomédica de Occidente del Instituto Mexicano del Seguro Social, Guadalajara, Mexico
| | | | | | | | | | | | | |
Collapse
|
9
|
Sorianello E, Schillaci R, Chamson-Reig A, Lux-Lantos V, Libertun C. Actions of immunosuppressor drugs on the development of an experimental ovarian tumor. Exp Biol Med (Maywood) 2002; 227:658-64. [PMID: 12192110 DOI: 10.1177/153537020222700816] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Immunosuppression has been related to the incidence of tumor apparition, including endocrine tumors. The intrasplenic ovarian tumor (luteoma) is a typical benign endocrine tumor that develops under high gonadotropin stimulation and, from the immunological perspective, is located in a critical organ involved in immune response. To establish if immunosuppression could alter the development of this experimental tumor, the effects of cyclosporin A (CsA) and dexamethasone (Dex) were evaluated. After surgery, tumor-bearing and sham animals were kept without treatment for 4 weeks; thereafter, they were distributed into CsA (25 mg/kg), Dex (0.1 mg/kg), or vehicle (75:25 castor oil:ethanol) groups and were injected on alternate days for 50 days. Body weight was evaluated weekly. Animals were sacrificed after a jugular vein blood sample was obtained. Thymi were weighed. Tumors were measured and placed in formaline for histological studies. Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL), and estradiol were measured by radioimmunoassay. Hematological parameters were determined. CsA induced a significant decrease in survival rates both in tumor-bearing and sham animals (P < 0.01). Dex significantly impaired weight increase in both groups of animals. CsA induced a significant weight loss in sham animals, not observed in tumor-bearing animals. Dex induced thymus weight loss in both groups, whereas CsA induced thymus weight loss only in sham animals. Only Dex induced a decrease in lymphocyte number in both groups. CsA induced an increase in monocyte number only in sham animals. Treatments did not alter LH, FSH, or estradiol, whereas PRL was increased by CsA only in sham rats. Neither Dex nor CsA induced any significant variations in tumor volume, nor did they alter tumor histology. In addition, no visible metastases or alterations in other organs were observed. We conclude that, though immunological parameters were altered by the treatments, immunosuppressor drugs did not condition tumor development. In addition, tumors secrete one or more factor/s that counteract CsA effect.
Collapse
Affiliation(s)
- E Sorianello
- Instituto de Biología y Medicina Experimental-Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Vuelta de Obligado 2490, (1428) Buenos Aires, Argentina
| | | | | | | | | |
Collapse
|
10
|
Porter RJ, Barnett NA, Idey A, McGuckin EA, O'Brien JT. Effects of hydrocortisone administration on cognitive function in the elderly. J Psychopharmacol 2002; 16:65-71. [PMID: 11949774 DOI: 10.1177/026988110201600106] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Previous studies have found adverse effects of both acute and chronic elevations of corticosteroids on cognitive function in humans and that cortisol levels may predict cognitive decline in elderly subjects. However, no previous studies have directly investigated the effects of hydrocortisone on cognitive functioning in the healthy elderly. Sixteen healthy elderly subjects took part in a placebo-controlled, double-blind, cross-over trial. Hydrocortisone 20 mg or placebo was administered twice, 12 h and 1 h before cognitive testing. On each occasion, a battery of neuropsychological tests was performed which included tests of attention, working memory, declarative memory and executive function. Salivary cortisol levels at the time of testing were elevated approximately 10-fold following hydrocortisone compared with placebo. No significant effects were found on memory or a range of other cognitive functions. The lack of effect of this regime of hydrocortisone is in contrast to studies in younger subjects. The elderly may be less sensitive to cognitive effects of short-term increases in cortisol levels, possibly due to an age-related downregulation of hippocampal glucocorticoid receptors.
Collapse
Affiliation(s)
- Richard J Porter
- Department of Psychological Medicine, Christchurch School of Medicine, New Zealand
| | | | | | | | | |
Collapse
|
11
|
Affiliation(s)
- B R Walker
- Department of Medical Sciences, University of Edinburgh, Western General Hospital, Edinburgh, UK.
| |
Collapse
|